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80%. Persistence was deﬁned as the number of days on thera-
pies until the ﬁrst 30-day gap. Propensity-score weighted logistic
regression and proportional hazard models were used to adjust
for baseline demographics, copay and pharmacy utilization vari-
ables. RESULTS: At baseline, across the SPAA and 2PAA groups
(N = 1,530), mean age was 62 years, 49% were female, 10%
utilized coronary vasodilators, 28% utilized anti-diabetics; mean
number of other baseline medications was 7. These characteris-
tics varied among all cohorts. Patients receiving SPAA were
nearly twice as likely to achieve adherence, and approximately
20% less likely to discontinue therapy at all doses; compared to
the European dose equivalents, the adjusted odds ratio of achiev-
ing adherence was 1.83 (95% conﬁdence interval (CI) 1.60–2.10,
P < 0.0001) and the discontinuation hazard ratio was 0.83 (CI
0.74–0.93, P = 0.0012). CONCLUSION: Single-pill amlodipine/
atorvastatin was associated with greater adherence and less dis-
continuation vs. 2-pill amlodipine and atorvastatin, at low, high,
and European doses of both medications.
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OBJECTIVES: Although guidelines recommend ﬁrst-line combi-
nation therapy for patients with severe hypertension, no quanti-
tative beneﬁt/risk estimate has been provided. The objective of
this study was to estimate these potential long-term beneﬁts and
risks based on results of a registrational clinical program.
METHODS: Results from a clinical study in severe hypertension
(diastolic blood pressure > = 110 mmHg) were used to project
beneﬁts and risks of irbesartan/hydrochlorothiazide (I/H) vs.
irbesartan monotherapy (I). In the randomized, controlled,
double-blind, 7-week trial (n = 695), initial I/H reduced exposure
to severe blood pressure (BP) levels (p = 0.0003) and provided an
additional BP reduction of approximately 10/5 mmHg (systolic/
diastolic) compared to I (p < 0.0001 for each parameter) with
similar safety. Beneﬁt was extrapolated by using cardiovascular
risks described in World Health Organization Guidelines. The BP
difference between I/H and I was applied conservatively to a time
frame of 0.1 to 0.8 years, as physicians in actual practice may
add adjunctive therapy after the initial prescription. The poten-
tial for serious adverse events from the use of I/H were estimated
based on post-marketing surveillance data (10 million patient
years of exposure to I/H) and literature review. RESULTS: A
population of 100,000 patients with severe hypertension is at
risk for between 2,500 and 10,000 cardiovascular events in one
year. Initial treatment with I/H instead of I is projected to prevent
between 100 and 1,000 events in one year. No signal of poten-
tially serious adverse events exists for I/H compared to I in
post-marketing data, but an estimate of between 0 to 3 such
events may be considered. CONCLUSION: The estimated
beneﬁt/risk of ﬁrst-line I/H is highly favorable, even when applied
to a short time horizon. This is because cardiovascular risk is the
greatest issue for the patient with severe hypertension. Earlier
and more extensive use of combination therapy can improve
public health.
PODIUM SESSION I: ECONOMICS OF DIABETES
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OBJECTIVES: A ﬁxed-effects (weighted average) meta-analysis
of three clinical trials showed the short-term therapy beneﬁts of
treating type 1 diabetic patients (mean age 40.3 years, duration
of diabetes 16.3 years, HbA1c 8.3%, BMI 25.2 kg.m-2) with
insulin detemir (IDet) versus neutral protamine Hagedorn (NPH)
insulin as the basal component of basal-bolus therapy when used
in combination with either insulin aspart (IAsp) or human
soluble insulin (HSI). METHODS: A published validated diabe-
tes model was used to estimate the long-term cumulative inci-
dence of complications, life expectancy (LE), quality-adjusted life
expectancy (QALE) and lifetime costs for IDet versus NPH regi-
mens. The short-term treatment effects (0.13% points lower
HbA1c, a 4% decrease in hypoglycaemic events and lower body
mass index 0.21 kg.m-2) observed in the meta-analyses were
projected using progression data derived from landmark clinical
and epidemiological studies. The costs of treating complications
in the German setting were taken from published sources and
total direct costs (complications + treatment costs) for each arm
were projected over patient lifetimes. Both costs and clinical
outcomes were discounted at 5% annually. RESULTS: The IDet
arm was associated with an increase in life expectancy, compared
to NPH, of 0.052 years (12.270  0.130 versus 12.218  0.121
years) with a resulting gain in QALE of 0.144 quality-adjusted
life years (QALYs) (6.23  0.07 versus 6.09  0.06 QALYs)
due to a reduction in diabetes-related complications. Increased
treatment costs for IDet resulted in greater total lifetime
costs per patient than with NPH (€91,960  2333 versus
€89,367  2183, difference €2,593), leading to an incremental
cost-effectiveness ratio of €18,070 per QALY gained. CONCLU-
SION: Short-term improvements seen with IDet versus NPH in
basal-bolus therapy were projected to show improvements in
both life expectancy and quality-adjusted life expectancy with a
cost-effectiveness ratio which fell well within the range usually
considered to represent value for money (<€50,000 per QALY
gained).
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OBJECTIVES: The aim of this analysis was to evaluate the
cost-utility of switching type 2 diabetes patients receiving human
soluble insulin (HSI) to rapid-acting insulin aspart (IAsp,
NovoRapid), with or without oral hypoglycemic agents, in the
German setting. METHODS: The CORE Diabetes Model, a
published and validated computer simulation model, was used to
project long-term clinical and economic outcomes associated
with IAsp and HSI treatment effects. The model is based on 15
semi-Markov sub-models representing the most important acute
and chronic diabetes-related complications including eye, renal
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